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Some drugs have pharmacologic effects when 
they interact with light. Certa in low-molecular-
weight, nuorescing chemicals of tricyclic structure 
absorb ultraviolet or visible light, providing energy 
for photochemical reactions. Nuclear, cytoplasmic. 
and cell membrane alterations can be induced in 
living cells; increasing doses of drug or light can 
cause death of bacteria, viruses, one-celled orga-
nisms, and tissue culture cells. Systemic or topical 
administration of t hese chemicals and subsequent 
exposure to the proper waveband of light can lead 
to e rythema of normal human skin. 
Photochemotherapy defines the combination of 
light and drug to bring about a beneficial effect. 
Usually, in the doses used , neither the drug alone 
nor the light alone has any significant biologic 
activity; it is only the combination of drug and 
light which is therapeutic . PUV A (psoralen and 
UV-A) is a term used to describe oral administra-
tion of psoralen and sub equent exposure to UV-A 
(long-wave ultraviolet light, 320-400 nm l. 
Certain fu rocoumarins. called psoralens. are t ri-
cyclic structures which may be con idered deriva-
tives of coumarin (Fig. 1). Although psoralens can 
be synthesized by adding a furan ring on a suitably 
sub tituted coumarin derivat.ive , the most pho-
toactive psoralens are found in nature in plants 
and microorganisms. Although the major absorp-
tion spectrum for psoralen lies bet.ween 210 and 
330 nm. the action spectrum for photo ensitization 
and photochemical changes is within wavelengths 
longer than :120 nm, In the presence of long-wave 
ultraviolet radiation (320-4oo nm. UV -A) these 
,ubstances induce a reversible cutaneous photo-
sensitivity manifested by what appears as an 
augmented sunburn reaction and subsequent 
hyperpigmentation [11 . The two psoralens com-
mercially avai lable in the United States. methox-
salen (B-methoxypsoralen. 8-MOP) and t rimethyl-
psora len (4,5 ' .B-trimethylpsoralen. TMP) are very 
potent photoactive drugs causing redness of nor-
mal human skin in }lg/cm' quantities applied 
topically if the skin is subsequently exposed to 
UV-A. When given orally, B-MOP is much more 
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erythemogenic and melanogenic than TMP for 
equivalent amounts of drug and UV-A. 
It has been shown that B-MOP and subsequent 
UV-A exposure leads to inhi bition of DNA synthe-
sis 12-41. Photoexcited psoralen molecules transfe r 
the absorbed ultraviolet energy to D A. Psoralen 
covalently binds to DNA forming monofunctional 
photoadducts with thymine bases and bifunctional 
interstrand cross-links between opposite pyrimi-
dine base pairs 15-7). Topical psoralens and UV-A 
exposure leads to regression of psoriatic plaques 
[8-10). 
This report summarizes the cutaneous effects of 
oral administration of 0.6 mg/kg of 8-MOP and 
subsequent exposure to UV-A. This drug-ligh t 
corn bination causes erythema and pigmentation of 
normal skin and has beneficial effects on psoriasis . 
The PUVA erythema reaction can be severe and 
is the limiting factor during treatment. While 
psoriasis treatment courses may require 10 to 20 
PUV A treatments. redness and pigmentation 
occur after a single PUV A exposure if doses of drug 
and light are adequate . The occurrence and degree 
of redness. however. is related to dose of both drug 
and light and is predictable. The erythema which 
results from PUVA differs from sunburn in its time 
course. PUVA redness may be absen t or just 
beginning at 12 to 24 hr after ult raviolet exposure 
(when UV-B or sunburn erythema is normally at 
its peak), and may peak at 4 to 72 hr or later. 
Since skin diseases can be treated at drug-l ight 
exposure doses which are less than the doses 
causing evere redness. careful dosimetry permits 
relatively safe PUVA treatments. 
The pigmentation which results from PUVA 
appears histologically and morphologically to be 
similar to normal melanogenesis (delayed tan-
ning). Pigmentation maxim izes about 5 to 7 days 
after PUVA exposure and lasts weeks to months. A 
patient's genetic ability to tan (facultative tan-
ning) dictates the degree and limits of delayed 
pigmentation. Baseline melanization (constitutive 
tanning) along with sunburn history, number of 
previous sun or PUVA exposures, and thickness of 
skin influence the amount of UV -A energy needed 
to penetrate into t.he skin to cause photobiologic 
reactions. In general, one or t wo erythemogenic 
PUVA exposures can stimulate melanogenesis t.o 
the same degree as can multiple UV-B or sun 
exposures. 
Redness, pigmentation, and therapeutic re -
sponses to PUVA depend on (1) the dose of drug, 
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(2) the time interval between ingestion and irradia-
tion (preirradiation period), and (3) the dose of 
light. Drug dose of 8-MOP is usually 0.6 mg/kg. 
Doses significantly higher than this may cause 
nausea and light-headedness in some patients. The 
pre irradiation period is 2 hr because the drug is 
maximally susceptible to photoactivation at that 
time (Fig. 2). It is important to note that the skin 
remains photosensitive to UV-A for 6 to 8 hr after 
ingestion. If prolonged sun exposure occurs, per-
sons a re at risk of exaggerated erythema from solar 
UV-A during the 6- to 8-hr period after ingestion. 
The dose of UV -A is given in joules/cm', a joule 
being 10 ' ergs. When speaking of energy dose one 
should also specify the unit of area and specify 
which wavelengths, frequency, or photon energy 
are being used. An example of a dose used to begin 
therapy in a Caucasian is 3.5 joules/em' of UV-A 
(320-400 nm 1. Initial UV -A exposure doses in 
Caucasians actually vary from 1.0 to 5.0 joules/ 
cm', depending on melanization and sunburn 
history. Exposure doses must be increased as 
tanning occurs. 
The ideal light source is one which has high-
intensity UV-A and om its most or all of wave-
lengths below 320 nm. High-intensity UV-A is 
needed to make treatment times shorter and more 
practical for the patient. Omission of the shorter, 
more erythemogenic wavelengths avoids the dis-
comfort and confusion of superimposing a sunburn 
reaction on the PUVA erythema reaction. Wave-
lengths shorter than 320 nm are as much as 1000 
times more efficient at causing erythema of normal 
Caucasian skin than is UV-A. Orally administered 
F,G . !. Psoralen. 
TRE.A:r'MENT TIME 
25-
4 
Haws 8fter ingestion of pscnlen 
FIG . 2. Relative UV· A photosensitivity after inges-
tion of 8-MOP. This relative photosensitivity is deter-
mined by delivering a fixed amount of UV-A at various 
times after ingestion of B- MOP and com paring the degree 
of erythema seen at 4B hr after radiation. 
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psoralens, in the dosage used for methoxsalen 
photochemotherapy, reduce this difference in ery-
themogenic potential to about 100-fold. The 
shorter wavelengths remain much more erythe· 
mogenic despite large doses of psoralens. 
To insure patient comfort. excessive amounts of 
visib le light and infrared radiation must also be 
omitted . Ideal light systems must a lso be large 
enough to radiate all exposed skin surfaces at once. 
The intensity should be uniform at varying dis -
tance from the light source so that all exposed skin 
surfaces receive the same dose of ultraviolet light. 
Accurate and reliable means of metering and 
delivering doses of light should be built into the 
treatment system. 
In initial studies performed in Boston [11 J and in 
Vienna 112J and in subsequent treatment of over 
300 additional patients (unpublished data l. re-
peated PUVA exposures (8 to 24) caused complete 
clearing of psoriasis in over 90% of patients. 
Another 8% of patients were more than 95 '* 
improved, and 2% of patients were not signifi-
cantly improved. In 54 bilateral compa'rison stud-
ies, PUVA was seen to be superior to conventional 
UV-B phototherapy. Maintenance therapy kept 
85o/c of patients free of psoriasis for up to 400 days 
[12J. 
Severe pruritus and marked redness in localized 
areas were seen often during the early phases of 
oral p oralen photochemotherapy but became less 
severe and less frequent as more experience was 
gained and dosimetry became more exact. In 
treatment of the last 100 patients. therapy has nol 
been interrupted because of itching or redness. 
although in 2% of patients both were a problem. 
No abnormalities in alkaline phosphatase, serum 
glutamic oxaloacetic transaminase. com plet e 
blood count, urinalysis. hilirubin, or blood urea 
nitrogen which could be attributed to photo-
chemotherapy were noted in any patient. 
Beca use the effects are limited to the skin 
ir radiated by UV.A, PUVA combines the ease of 
administration of oral medication with the safety 
of topical medication. However, scalp and body 
folds do not respond if light does not reach those 
areas. The scalp of bald patients or persons with 
short haircuts responds well. Patients do not have 
to be hospitalized for therapy. Infrequent treat-
ments are required (2 to 3 times per week) and it 
appears that weekly maintenance keeps most 
patients free of psoriasis for months . While the 
acute limiting factor of the PUV A reaction is 
erythema, this can be avoided by careful dosime· 
try. 
Large doses of 8- MOP and long exposures 10 
high-intensi ty UV -A causes skin cancer and cat~­
racts in laboratory animals. These. effects have not 
been seen in man in over 20 years of use of 
methol(salen and UV -A for treatment of vitiligo. 
These side effects may not be produced in humans 
in the dose of drug and light used or they may be ,0 
infrequent that they have not come to the atten· 
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tion of the clinician. Careful observation and 
prospective studies are needed. It may also be that 
repeated phototoxic reactions over many years 
may lead to actinic changes in the skin, especially 
skin which pigments poorly or not at all. On the 
other hand, patients who tan well may actually be 
protected by PUV A; the striking melanogenesis, by 
acting as a sunscreen, may permit less cumula tive 
solar-induced changes over many decades. The 
physician must weigh the theoretical risks and the 
psychological stress of psoriasis against the bene-
fits of effective photochemotherapy. 
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